Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

NCT02547805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperoxaluria
Nephrolithiasis
Hyperoxaluria
Kidney Stones
Dietary Hyperoxaluria

Interventions

DRUG: ALLN-177
DRUG: Placebo

Sponsor

Allena Pharmaceuticals